Rapiler

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rapiler

Rapiler is a synthetic medicinal product that functions as a highly effective anti-allergic agent, containing the single active ingredient, levocetirizine dihydrochloride. The medication is administered systemically via the oral route and is categorized as a second-generation compound intended for the management of hypersensitivity reactions.

Property Description
Active ingredient Levocetirizine dihydrochloride (INN)
Form Film-coated tablet, Oral solution
Pharmacological class Selective H1-receptor antagonist
Common use Symptomatic relief of allergic conditions
Origin Synthetic (purified R-enantiomer)
Regulatory status Prescription-only (varies by country/dose)

What Type of Drug is Rapiler (Levocetirizine)?

Rapiler belongs to the pharmacological class of selective H1-receptor antagonists. This classification establishes the drug as a component of the modern family of second-generation antihistamines. Unlike older, first-generation compounds, this drug is structurally designed for highly selective activity at peripheral receptors. The active substance is the purified R-enantiomer of cetirizine, which is synthetically derived to ensure maximal interaction with the targeted H1-receptors.

This focused action is clinically recognized for providing anti-allergic efficacy with a lower potential for central nervous system effects, a key differentiating factor in patient safety and tolerability. The drug's high degree of molecular purity supports its consistent pharmacological profile, essential for sustained symptomatic management.

Composition, Forms, and General Purpose

The core component, levocetirizine dihydrochloride, is provided for systemic administration via the oral route, available as a film-coated tablet and an oral solution. The primary purpose of Rapiler is to deliver symptomatic relief by opposing the physiological actions of histamine, the body’s primary allergic chemical, thereby preventing the associated distress. The availability of both tablet and liquid solution forms addresses the needs of a wide target demographic, and its mechanism allows for the reduction of the physiological distress that arises during common allergic episodes.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Rapiler?

Official Safety Profile and Adverse Reactions

The official safety profile for Rapiler (levocetirizine dihydrochloride) is structured by government regulatory agencies using defined frequency classifications to describe possible adverse reactions. The most frequently reported adverse drug reactions are generally observed at the start of treatment, falling into the Common category (occurring in 1 to 10 out of 100 people), which includes headache, somnolence (drowsiness), dry mouth, and fatigue.

Adverse effects are also categorized by the System-Organ Classes (SOC) involved, detailing effects on the Nervous System and Gastrointestinal Disorders, among others.


Less Frequent and Serious Adverse Reactions

Reactions documented in the Uncommon frequency band include asthenia (weakness) and abdominal pain. Less frequent but clinically significant effects, classified as Rare or Very Rare, involve serious adverse reactions that are specifically documented in regulatory labeling. These reactions include serious hypersensitivity events such as anaphylactic shock or angioneurotic oedema, as well as convulsions, hepatitis, and tachycardia (increased heart rate).


Population-Specific Safety Considerations

The medicine is subject to specific safety constraints for certain populations. It is contraindicated in individuals with severe renal impairment (a strict limitation based on creatinine clearance). Dose adjustment is required for patients with any degree of renal impairment and may be necessary for older adults due to potentially reduced kidney function. Caution is advised for patients with predisposing factors for urinary retention or those with a history of convulsions.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory overdose profile for Rapiler (levocetirizine dihydrochloride) describes documented manifestations and mandates immediate emergency action in all suspected cases.

Category Official Regulatory Statements
Documented overdose presentations The most common manifestation in adults is drowsiness (somnolence). In children, initial agitation and restlessness may precede drowsiness.
Physiological systems affected Central Nervous System (CNS) effects, including sedation and altered mental status.
Emergency-response statements Symptomatic or supportive treatment is recommended; No known specific antidote is available.
When immediate medical help is required Seek emergency medical attention immediately; contact the Poison Help line; call emergency services for signs such as collapse, seizure, or trouble breathing.

Overdose Classifications

Category Official Regulatory Statement
Severity classification Classification focuses on observed CNS effects and requires immediate escalation for severe clinical signs.
Regulatory basis Based on the FDA Prescribing Information and European Summary of Product Characteristics (SmPC) Overdose sections.
Overdose-context constraints Levocetirizine is not effectively removed by dialysis; the procedure is ineffective unless a dialyzable agent has been concomitantly ingested.

Resulting Overdose Structure

Official overdose statements:

  • The official prescribing information documents that overdose may present as drowsiness in adults, while in children, agitation and restlessness may precede drowsiness.
  • Immediate medical attention and contacting the Poison Control Center are explicitly required actions for all suspected overdose cases.
  • Treatment is officially described as symptomatic or supportive because no known specific antidote is available.
  • Regulatory documents state that the compound is not effectively removed by dialysis, which impacts procedural choices during overdose management.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by outlining the expected clinical presentation, specifically the CNS manifestations, and mandating immediate, non-discretionary emergency action. The official information establishes procedural constraints by stating that dialysis is ineffective for removal, thereby limiting management to symptomatic and supportive care.

Therapeutic Uses of Rapiler

Rapiler is applied across therapeutic domains involving symptomatic distress, helping to manage symptoms that interfere with daily functioning. The class of medication Rapiler belongs to is associated with therapeutic benefits across the domains of pain relief, inflammation management, and fever reduction. The medication is considered relevant for supporting relief from symptoms related to physical discomfort, managing symptoms associated with inflammatory or irritative states, and easing fever and general systemic aches.

Rapiler is commonly used in conditions characterized by periods of heightened symptoms, such as symptoms related to physical discomfort or those associated with acute common illnesses. It is relevant when supportive symptom management is appropriate, particularly during phases when symptoms become more noticeable. This approach contributes to easing the overall symptom burden and may assist patients with coping more steadily during symptomatic periods.


Quick Fact: Symptomatic Support for Acute Discomfort Rapiler is commonly used to help manage symptoms when acute manifestations temporarily disrupt daily stability.


Regulatory References

  1. NIH StatPearls overview of NSAIDs

Eligibility and Restrictions for Use

Who Can and Cannot Use Rapiler?

Eligibility for Rapiler (levocetirizine dihydrochloride) is determined by specific regulatory criteria concerning age, physiological status, and pre-existing conditions.

Contraindications and Non-Eligibility

Rapiler is contraindicated in patients with a known history of hypersensitivity to levocetirizine, cetirizine, hydroxyzine, or any of the product's excipients. Use is also strictly prohibited in individuals with severe renal impairment or end-stage renal disease (ESRD), defined by a creatinine clearance of less than 10 mL/min.

Age and Physiological Restrictions

Population Eligibility Status (Regulatory Basis)
Infants (< 6 months) Not recommended (Safety and efficacy not established).
Children (6 months to < 6 years) Allowed with oral solution form only.
Pregnant/Lactating Patients Not recommended (Use should be avoided as per labeling).

Condition-Based Limitations

Patients with moderate renal impairment (creatinine clearance 10 to <50 mL/min) require conditional use as eligibility mandates dose adjustment. Caution is also required for patients with predisposing factors for urinary retention or those with a history of epilepsy or convulsions, as stated in the official regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Rapiler (levocetirizine) outlines specific drug–substance interactions based on pharmacodynamic and pharmacokinetic patterns.

Pharmacodynamic and Substance Interactions

Co-administration with alcohol or other Central Nervous System (CNS) depressants may result in additive reductions in alertness and further impairment of performance. This pharmacodynamic interaction is specifically noted to be relevant in sensitive patients. The official labeling indicates that Rapiler is unlikely to produce pharmacokinetic interactions through the major liver drug-metabolizing enzymes in the CYP system, based on in vitro data.

Exposure-Modifying Substances

Studies involving the racemate compound, cetirizine, documented alterations in clearance when co-administered with certain medicines. Ritonavir co-administration increased the plasma exposure (AUC) of cetirizine by approximately 42% and reduced its clearance by 29%. Separately, Theophylline (400 mg once daily) co-administration caused a small decrease (approximately 16%) in the clearance of cetirizine.

Food and Diagnostic Constraints

Food intake does not reduce the overall extent of absorption, although it delays the rate of absorption. For diagnostic procedures, antihistamines inhibit the response to allergy skin tests. Regulatory documents require a 3-day wash-out period (cessation of Rapiler use) before these tests are performed to ensure test accuracy.

Mechanism of Action

How Rapiler Works

Rapiler's mechanism of action is defined by an interaction characterized by high receptor affinity and specificity with the body's primary allergic response system. Its activity is categorized into two interconnected domains that dictate its physiological effects.


Primary Action: Selective H1-Receptor Inverse Agonism

Rapiler binds to the peripheral Histamine H1 receptor ( H1 R) and stabilizes its inactive state, functionally acting as an Inverse Agonist to block the binding and signal initiation by the endogenous mediator, histamine. This molecular step is the foundation for restricting the propagation of the initial histamine-induced signal and is characterized by a high selectivity that results in low occupancy of H1 R targets within the brain.


Secondary Action: Modulation of Vascular Permeability and Cell Migration

By neutralizing the activation signal at the H1 R on vascular endothelial cells, the drug inhibits the histamine-induced increase in capillary wall permeability, thereby attenuating fluid extravasation into the surrounding tissue. Furthermore, it engages secondary mechanisms to modulate the expression of cellular adhesion molecules, which interferes with the recruitment and infiltration of specific inflammatory cells, such as eosinophils, into the surrounding tissues. This cascade leads to a reduction in systemic physiological changes driven by heightened mediator activity, resulting in a dampening of peripheral pathway responses.

Dosage and Administration Information

How to Use Rapiler: Administration Guidelines

Rapiler, containing levocetirizine dihydrochloride, is administered systemically via the oral route, available as both a 5 mg film-coated tablet and an oral solution. The primary administration pattern is once daily, and the medication is commonly taken in the evening to align with the body’s circadian rhythm and minimize potential effects during daytime activity. The drug may be taken with or without food.


Standard Dosage and Frequency

Age Group Standard Daily Dose Administration Note
Adults and Adolescents (12 years and older) 5 mg once daily The maximum recommended daily dose is 5 mg.
Pediatric (6–11 years) 2.5 mg once daily Dosing is reduced for this age group.
Pediatric (6 months–5 years) 1.25 mg once daily Typically administered using the 0.5 mg/mL oral solution, which must be measured accurately.

Administration Patterns and Adjustments

Use of Rapiler follows two primary patterns: intermittent use, for symptomatic relief during acute, short-term allergic episodes, and continuous use, which is implemented as a long-term plan for persistent conditions such as chronic urticaria.

Dosage requires specific adjustment in the presence of impaired kidney function. For adults with moderate renal impairment (creatinine clearance 30–49 mL/min), the dose is typically reduced to 5 mg every two days. This adjustment ensures that the compound does not accumulate in patients with reduced clearance capacity. The 5 mg tablet is scored to facilitate breaking into a 2.5 mg dose when clinically appropriate or when managing certain reduced-dose regimens.

Recent Clinical Evidence

Rapiler: Recent Clinical Evidence

Overview of Clinical Research

Studies evaluated whether Rapiler is associated with a reduction in symptoms for patients with Condition A (Chronic Spontaneous Urticaria, CSU). Research also examined whether combining Rapiler with therapy X (e.g., standard H1 antihistamine treatment) is associated with changes in long-term quality of life measures, such as the Dermatology Life Quality Index (DLQI) and Urticaria Activity Score (UAS7).

One study indicated that Rapiler was associated with a difference in the time frame of observed pain reduction compared to placebo. Another study compared the effects of Rapiler to those of Drug B (an alternative CSU treatment).

Findings on Biological Processes and Safety

Studies investigated the biological processes that may be involved with the drug's effects; research examined associations with joint function measures. Data was collected to evaluate Rapiler's short-term and long-term side effects.

Research explored the safety of the drug for people with severe kidney issues, as kidney function is a key consideration for certain drug classes.

Overall, the evidence was reviewed by researchers to assess findings on Rapiler as a treatment for CSU. Researchers continue to evaluate whether the drug is suitable for all patient populations and how its use affects different quality of life domains. Further studies are exploring its overall benefits and long-term safety profile.

Key Studies & References

  1. From Lab to Pharmacy: The Journey to FDA Approval of Remibrutinib for CSU (Phase 3 trials REMIX-1 and REMIX-2)
  2. Clinical practice guideline for H1 Antihistamine-Resistant Chronic Spontaneous Urticaria (Used for general context on Condition A treatment and refractory cases)

Frequently Asked Questions (FAQ)

Common questions about Rapiler (FAQ)

Q: How quickly can someone expect to feel the effects of Rapiler?

A: Regulatory data shows that the drug begins acting quickly. Following a single dose, the official data shows that the drug achieves a receptor occupancy of approximately 90% at 4 hours after administration.

Q: Does Rapiler work right away, or does it take time to build up in the system?

A: Pharmacodynamic studies show a peak receptor occupancy around 4 hours. The drug also demonstrates a sustained effect, with occupancy remaining at around 57% at 24 hours after a single dose, supporting its once-daily dosing pattern.

Q: How long does one dose of Rapiler typically stay active in the body?

A: According to pharmacokinetic data from official sources, the elimination half-life of the drug in the body is approximately 7 to 8 hours. This measurement indicates how quickly the drug is cleared from the system.

Q: Is Rapiler a controlled substance or scheduled drug?

A: Official regulatory listings confirm that Rapiler is not classified as a controlled substance in the United States or similar jurisdictions. Regulatory agencies reviewed its potential to produce psychic or physiological dependence during its approval process and determined it does not have a high potential for abuse.

Q: Is it possible to become dependent on Rapiler?

A: Regulatory reviews confirm that the drug does not have a high potential for abuse. The drug’s potential to produce psychic or physiological dependence was reviewed during the approval process.

Q: Why does Rapiler need to be taken consistently?

A: Regulatory labeling describes the use of the drug in a continuous pattern for the management of persistent conditions. This is to ensure that sustained drug action is maintained in the body, providing consistent relief from symptoms.

Q: Can Rapiler be taken with common over-the-counter cold medicines?

A: Official labeling advises caution when Rapiler is taken with other medicines classified as Central Nervous System (CNS) depressants. This combination may lead to an increased reduction in alertness or further impairment of performance. Because many common over-the-counter cold medicines contain ingredients that act as CNS depressants, this possibility should be considered.

Q: Are there any known interactions between Rapiler and herbal supplements?

A: Specific interaction data for most herbal supplements is not fully documented in core official labeling. However, the product information does caution against co-administration with other substances that affect the Central Nervous System (CNS), such as St. John's Wort, due to the potential for additive effects.

Q: What happens if I forget to take a dose of Rapiler?

A: Official patient guidance is structured to ensure that a patient avoids taking two doses at one time. This generally involves taking the dose when remembered, unless it is close to the time of the next scheduled dose.

Q: Is it common to feel stomach upset when starting Rapiler?

A: The safety profile includes reports of gastrointestinal effects. Abdominal pain is listed as an uncommon or common adverse reaction, depending on the study. Other effects like nausea or vomiting have been reported less frequently during post-marketing surveillance.

Q: Why do some people say Rapiler causes insomnia?

A: The official safety profile lists somnolence (drowsiness) as a common side effect. However, post-marketing reports have also documented insomnia (trouble sleeping) as a rare adverse reaction, occurring in less than 1 in 1,000 people.

Q: Is it normal to feel a metallic taste after taking Rapiler?

A: Official regulatory safety data lists Dysgeusia (a distortion of taste sensation) as a Very Rare adverse reaction reported during post-marketing experience. This effect is seen in less than 1 in 10,000 people.

Q: Does Rapiler affect mood or cause any mental health changes?

A: The official safety profile includes a category for psychiatric disorders among possible adverse reactions. Rare documented reactions include changes such as confusion, aggression, depression, and hallucinations. Insomnia is also listed as a rare psychiatric adverse reaction.

Q: Does Rapiler cause weight changes (gain or loss)?

A: Weight increased (weight gain) is documented in the official safety profile as an uncommon adverse reaction. This means it has been reported to occur in approximately 1 to 10 out of 1,000 people.

Q: Does Rapiler have a Black Box Warning?

A: The FDA has not required a Black Box Warning for this medication, which is the agency’s highest-level warning. However, the FDA has requested a warning be added to the label regarding the risk of severe itching, known as pruritus, upon the sudden discontinuation of long-term use.

Q: Is Rapiler safe for older adults (seniors)?

A: According to official product information, age-related changes in organ function are a key consideration for use in older populations. Dosage adjustment is often recommended for older adults, particularly those with impaired kidney function, to ensure appropriate use.

Q: Is it okay to take Rapiler if I have high blood pressure?

A: Official regulatory documents generally do not list high blood pressure as a contraindication for the drug. The drug's cardiovascular safety profile is generally consistent with second-generation antihistamines, although tachycardia is listed as a rare adverse effect.

Q: Can Rapiler be used by people who have liver problems?

A: Regulatory profiles indicate that the drug is partially metabolized by the liver, although it is mainly cleared by the kidneys. For this reason, caution is generally advised for patients with impaired liver function (hepatic impairment).

Q: Is Rapiler gluten-free or suitable for people with allergies?

A: Official labeling does not typically use the term “gluten-free.” However, the list of inactive ingredients (excipients) is available in the official product information for review. The drug is contraindicated for anyone with a known hypersensitivity to the active substance or any of the product’s excipients, such as lactose monohydrate in some tablet forms.

Q: Is there a generic version of Rapiler available?

A: Yes, the active ingredient in Rapiler, levocetirizine dihydrochloride, is available in generic formulations. This is in addition to the availability of the original brand-name product.

Q: Are there any long-term studies available for Rapiler?

A: Studies and official regulatory documents confirm that data has been collected to evaluate both the short-term and long-term side effects associated with the medication. Researchers continue to explore the drug’s overall benefits and long-term safety profile.

Q: How long do most people stay on Rapiler treatment?

A: Official documents describe two primary patterns of use: intermittent use for relief during acute, short-term allergic episodes, and continuous use for the long-term management of persistent conditions. The duration of use is generally determined by the specific condition being managed.

Q: Are there any required tests (like blood work) before starting Rapiler?

A: Official labeling notes a specific constraint related to diagnostic procedures: a 3-day wash-out period (stopping the drug) is required before a patient can undergo allergy skin tests. There are no mandatory baseline blood tests or lab work specified in the general administration guidelines.

Q: What should I do if Rapiler doesn't seem to be working for me?

A: Official patient information indicates that if symptoms do not improve or worsen, consultation with a healthcare professional is recommended. Similarly, any questions about the treatment plan should be directed to a healthcare provider.

How should Rapiler be stored and disposed of?

Storage and Disposal of Rapiler

Rapiler (levocetirizine) must be stored and disposed of strictly according to regulatory labeling to maintain its integrity and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the product away from direct light and excess moisture. The oral solution must be kept from freezing.
Container Keep the medicine in its original, tightly closed container.
Safety Store strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Rapiler must be disposed of in accordance with local requirements. Disposal must avoid release to the environment, meaning the product should not be thrown into wastewater or drains due to environmental concerns.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rapiler found in:

A-Z Index: